Combined THC and CBD Drops for Treatment of Crohn's Disease

Last updated: March 7, 2019
Sponsor: Meir Medical Center
Overall Status: Completed

Phase

1/2

Condition

Crohn's Disease

Ulcerative Colitis

Colic

Treatment

N/A

Clinical Study ID

NCT01826188
0196-12-MMC
  • Ages 20-85
  • All Genders

Study Summary

There are many reports about efficacy of Cannabis in Crohn's disease but no controlled trials. The aim of the proposed trial is to investigate the efficacy of oil containing the cannabinoids THC and CBD given by mouth for induction of remission in Crohn's disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients with a diagnosis of Crohn's disease of at least 3 months duration, which wasproved by either endoscopy or appropriate imaging study.

  2. Patients who have failed treatment with either 5 ASA or corticosteroids orimmunomodulators or biologic agents, or steroid dependant patients, or patients whowere treated by the above mentioned drugs and could not tolerate them due to sideeffects.

  3. Age 20 or older.

  4. Able to sign informed concent

  5. Active Crohn's disease with a CDAI 200 or more.

Exclusion

Exclusion Criteria:

  1. Patients with a diagnosis of a mental disorder

  2. Patients who by the judgment of their physician are likely to develop drug addiction.

  3. Pregnant women or women who are intending to become pregnant

  4. Patients with a known cannabis allergy

  5. Patients who are not capable of giving an informed consent

  6. Patients with an impending operation due to Crohn's disease.

Study Design

Total Participants: 50
Study Start date:
March 01, 2013
Estimated Completion Date:
June 30, 2018

Study Description

The investigators have recently published a retrospective observational study about the beneficial effect of cannabis in Crohn's disease. The investigators have also concluded a double blind placebo controlled study of Inhaled cannabis in the treatment of Crohn's disease. Both studies have shown significant symptomatic improvement of disease. However, objective parameters of inflammation were not measured. The question arises as to whether the observed improvement is merely symptomatic or due to a real change in inflammation. In addition, administration per os is a healthier option than smoking but the efficacy of oral cannabis was not investigated.

The aim of the proposed study in to evaluate the efficacy of drops of cannabis oil in crohn's disease patients compared to placebo. Treatment success will be defined as a decrease of at least 100 points in CDAI after 8 weeks of treatment.

Secondary aims:

  1. Remission of disease i.e CDAI of less the 150 points.

  2. Improvement of at least one point in Endoscopic disease activity index

  3. Improvement of CRP and calprotectine

  4. Improvement of blood cytokine levels

  5. Improvement of at least 30 points in quality of life as measured by the SF 36. In addition the investigators will monitor side effects by questionnaires addressed to the patients and to a significant relative of the patients.

Connect with a study center

  • Meir Hospital

    Kfar Saba,
    Israel

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.